Apoptosis in favourable neuroblastomas is not dependent on Fas (CD95/APO-1) expression but on activated caspase 3 (CPP32)

Journal of Pathology

Volumn 189, Issue 3, 1999, Pages 410-415

  Koizumi, Hirotaka ^a   Ohkawa, Ikuo ^a   Tsukahara, Toshifumi ^b   Momoi, Takashi ^b   Nakada, Koonosuke ^a   Uchikoshi, Toshiyuki ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Apoptosis; Caspase 3; CPP32; Fas; Fas ligand; Neuroblastomas; Tumour regression

Indexed keywords

CASPASE 3; FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; ENZYME ACTIVATION; ENZYME LOCALIZATION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

ANTIGENS, CD95; APOPTOSIS; CASPASE 3; CASPASES; ENZYME ACTIVATION; ENZYME PRECURSORS; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; LIGANDS; NEUROBLASTOMA;

EID: 0032858126     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199911)189:3<410::AID-PATH453>3.0.CO;2-H     Document Type: Article

References (31)

1. Berthold F. Overview: biology of neuroblastoma. In: Pochedly C, ed. Neuroblastoma: Tumor Biology and Therapy. Florida: CRC Press, 1990; 1-30.
2. Ikeda Y, Lister J, Buyukpamukcu M. Congenital neuroblastoma in situ, and the normal fetal development of the adrenal. J Pediatr Surg 1981; 16: 636-644.
3. Shimada H. Neuroblastoma. Pathology and biology. Acta Pathol Jpn 1992; 42: 229-241.
4. Evans AE, D'Angio GJ, Randolph JA. A proposed staging for children with neuroblastoma: Children's Cancer Study Group. Cancer 1971; 27: 374-378.
5. Ninane J, Pritchard J, Morris-Jones P. Mann JR, Malpas JS. Stage II neuroblastoma: adverse prognostic significance of lymph node involvement. Arch Dis Child 1982; 57: 438-442.
6. Tonini GP, Mazzocco K, di Vinci A, et al. Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors. J Neurooncol 1997; 31: 209-215.
7. Koizumi H, Wakisaka M, Nakada K, et al. Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression. Virchows Arch 1995; 427: 167-173.
8. Pritchard J, Hickman JA. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994; 344: 869-870.
9. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
10. Debatin K.-M. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ 1996; 3: 185-189.
11. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997; 22: 299-306.
12. Fernandez-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 1994; 269: 30 761-30 764.
13. Schlegel J, Peters, I, Orrenius S, et al. CPP32/apopain is a key interleukin 1β converting enzyme like protease involved in Fas-mediated apoptosis. J Biol Chem 1996; 271: 1841-1844.
14. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
15. Goillot E, Raingeaud J, Ranger A, et al. Mitogen-activated protein kinase-mediated Fas apoptotic signalling pathway. Proc Natl Acad Sci U S A 1997; 94: 3302-3307.
16. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
17. Nakagawara A, Nakamura Y, Ikeda H, et al. High levels of expression and nuclear localization of interleukin-1β converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res 1997; 57: 4578-4584.
18. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of International Criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
19. Fujita E, Kouroku Y, Miho Y, et al. Wortmannin enhances activation of CPP32 (caspase-3) induced by TNF or anti-Fas. Cell Death Differ 1998; 5: 289-297.
20. Kouroku Y, Urase K, Fujita E, et al. Detection of activated caspase-3 by a cleavage site-directed antiserum during naturally occuring DRG neuron apoptosis. Biochem Biophy Res Commun 1998; 247: 780-784.
21. Bobrow MN. Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods 1989; 125: 279-285.
22. Kobayashi T, Shiozaki A, Momoi T, Arahata K. Tsukahara T. Identification of an interleukin-1β converting enzyme-like activity that increases upon treatment of P19 cells with retinoic acid as the proteasome. J Biochem 1996; 120: 699-704.
23. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
24. Knox K, Gordon J. Regulation of apoptosis in germinal centre B cells. Immunol Today 1995; 16: 106-107.
25. Walker P, Saas P, Dietrich P. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521-4524.
26. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
27. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-XL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996; 56: 4743-4748.
28. Castle VP, Heidelberger KP, Bromberg J, et al. Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and N-mjc amplification. Am J Pathol 1993; 143: 1543-1550.
29. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
30. Mukasa T, Urase K, Momoi YM, Kimura I, Momoi T. Specific expression of CPP32 in sensory neurons of mouse embryos and activation of CPP32 in the apoptosis induced by a withdrawal of NGF. Biochem Biophys Res Commun 1997; 231: 770-774.
31. Shiokawa D, Ohyama H, Yamada T, Tanuma S. Purification and properties of DNase gamma from apoptotic rat thymocytes. Biochem J 1997; 326: 675-681.